Search for 'Provider:Endocrine Related Cancer,'

Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

By Martínez López, Joaquín. Endocrine-related cancer, 2015 . 22(4):545-59. , Formato Vancouver: Ríos R, Lupiañez CB, Campa D, Martino A, Martínez López J, Martínez Bueno M et al. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer. 2015 Aug;22(4):545-59. doi: 10.1530/ERC-15-0029. Epub 2015 Jun 22..

Place Hold on Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium.

Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.

By Bernal González, Carmen. Endocrine-Related Cancer, 2013 . 20(4):477-93. , Formato Vancouver: De Cubas AA, Leandro-García LJ, Schiavi F, Mancikova V, Comino-Méndez I,Inglada-Pérez L et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocr Relat Cancer. 2013 Jun 24;20(4):477-93.

Place Hold on Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways.

Sorafenib in metastatic thyroid cancer.

By Iglesias Docampo, Lara. Endocrine Related Cancer, 2012 . 19(2):209-16. , Formato Vancouver: Capdevila J, Iglesias L, Halperín I, Segura A, Martínez-Trufero J, Vaz MÁ, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer. 2012 Apr 10;19(2):209-16.

Place Hold on Sorafenib in metastatic thyroid cancer.